Premier Path Wealth Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.26M Buy
6,238
+149
+2% +$51K 0.26% 90
2026
Q1
$2.14M Buy
6,089
+1,388
+30% +$495K 0.28% 83
2025
Q4
$1.54M Buy
4,701
+2
+0% +$634 0.2% 107
2025
Q3
$1.33M Sell
4,699
-19
-0.4% -$5.51K 0.17% 126
2025
Q2
$1.32M Buy
4,718
+80
+2% +$22.7K 0.18% 129
2025
Q1
$1.44M Buy
4,638
+205
+5% +$60.5K 0.22% 106
2024
Q4
$1.16M Sell
4,433
-47
-1% -$13.9K 0.18% 141
2024
Q3
$1.44M Buy
4,480
+67
+2% +$21.9K 0.23% 109
2024
Q2
$1.38M Buy
4,413
+697
+19% +$205K 0.24% 103
2024
Q1
$1.06M Buy
3,716
+24
+0.7% +$7.02K 0.2% 134
2023
Q4
$1.06M Buy
+3,692
New +$1.01M 0.24% 110

Other funds holding AMGN

Premier Path Wealth Partners's AMGN Position: Q2 2026 in Review

Premier Path Wealth Partners increased its Amgen (AMGN) stake by 2.4% in Q2 2026, buying an estimated $51K and bringing the position to 6,238 shares worth $2.26M. The position accounts for 0.26% of the portfolio, ranked #90.

Premier Path Wealth Partners first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. 1,372 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Premier Path Wealth Partners held 6,238 shares of Amgen worth $2.26M as of Q2 2026.
  • Premier Path Wealth Partners bought 149 Amgen shares in Q2 2026, an estimated $51K.
  • Amgen made up 0.26% of Premier Path Wealth Partners's portfolio in Q2 2026, its #90 holding.
  • Premier Path Wealth Partners first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • 1,372 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.